WO2002067895A3 - Implant dosage form and use thereof for the delivery of a cholesterol lowering agent - Google Patents
Implant dosage form and use thereof for the delivery of a cholesterol lowering agent Download PDFInfo
- Publication number
- WO2002067895A3 WO2002067895A3 PCT/US2001/046714 US0146714W WO02067895A3 WO 2002067895 A3 WO2002067895 A3 WO 2002067895A3 US 0146714 W US0146714 W US 0146714W WO 02067895 A3 WO02067895 A3 WO 02067895A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery
- lowering agent
- cholesterol lowering
- dosage form
- implant dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2429898A CA2429898C (en) | 2000-11-16 | 2001-11-08 | Devices and methods for cholesterol management |
EP01273052A EP1335704A2 (en) | 2000-11-16 | 2001-11-08 | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
US10/432,644 US20040142902A1 (en) | 2001-11-08 | 2001-11-08 | Implant dosage form and use thereof for the delivery of a cholosterol lowering agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24964400P | 2000-11-16 | 2000-11-16 | |
US60/249,644 | 2000-11-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002067895A2 WO2002067895A2 (en) | 2002-09-06 |
WO2002067895A3 true WO2002067895A3 (en) | 2003-04-17 |
Family
ID=22944385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/046714 WO2002067895A2 (en) | 2000-11-16 | 2001-11-08 | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1335704A2 (en) |
CA (1) | CA2429898C (en) |
WO (1) | WO2002067895A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2342118C2 (en) * | 2002-12-19 | 2008-12-27 | Алза Корпорейшн | Stable nonaqueous single-phase gels and compositions on their basis for delivery from implanted device |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
TW200505500A (en) | 2003-03-31 | 2005-02-16 | Alza Corp | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
AU2004227985B2 (en) | 2003-03-31 | 2009-04-02 | Intarcia Therapeutics, Inc. | Osmotic pump with means for dissipating internal pressure |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
CN101715340A (en) | 2007-04-23 | 2010-05-26 | 精达制药公司 | The mixed suspension preparation of insulinotropic peptide and application thereof |
CN101677952B (en) * | 2007-05-18 | 2012-12-05 | 杜雷科特公司 | Improved depot formulations |
MX354603B (en) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Sustained delivery formulations of risperidone compounds. |
PT2462246T (en) | 2009-09-28 | 2017-12-11 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
SG10201510484YA (en) * | 2010-12-20 | 2016-01-28 | Cormatrix Cardiovascular Inc | A drug eluting patch for the treatment of localized tissue disease or defect |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2013049595A1 (en) * | 2011-09-29 | 2013-04-04 | Ethicon Endo-Surgery, Inc. | Methods and compositions of bile acids |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
EA033537B1 (en) | 2013-03-11 | 2019-10-31 | Durect Corp | Injectable controlled release composition comprising high viscosity liquid carrier |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
ES2968262T3 (en) | 2015-06-03 | 2024-05-08 | I2O Therapeutics Inc | Implant placement systems |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
IL267736B2 (en) | 2017-01-03 | 2024-03-01 | Intarcia Therapeutics Inc | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
CN115666621A (en) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | Sustained release drug delivery systems with reduced impurities and related methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0503520A1 (en) * | 1991-03-12 | 1992-09-16 | Glaxo Group Limited | Cyclic ketal derivatives |
US5837228A (en) * | 1990-08-22 | 1998-11-17 | Merck & Co., Inc. | Bioerodible implants |
WO2000004897A1 (en) * | 1998-07-20 | 2000-02-03 | Peptech Limited | Bioimplant formulation |
-
2001
- 2001-11-08 WO PCT/US2001/046714 patent/WO2002067895A2/en not_active Application Discontinuation
- 2001-11-08 CA CA2429898A patent/CA2429898C/en not_active Expired - Fee Related
- 2001-11-08 EP EP01273052A patent/EP1335704A2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837228A (en) * | 1990-08-22 | 1998-11-17 | Merck & Co., Inc. | Bioerodible implants |
EP0503520A1 (en) * | 1991-03-12 | 1992-09-16 | Glaxo Group Limited | Cyclic ketal derivatives |
WO2000004897A1 (en) * | 1998-07-20 | 2000-02-03 | Peptech Limited | Bioimplant formulation |
Non-Patent Citations (5)
Title |
---|
DATABASE SCISEARCH [online] BUCHWALD H (REPRINT): "CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY", XP002221937, retrieved from STN Database accession no. 292994 * |
DATABASE SCISEARCH [online] JOLES J (REPRINT) ET AL: "SUBCUTANEOUS ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS IN HYPERLIPEMIC AND NORMAL RATS", XP002221936, retrieved from STN Database accession no. 610133 * |
LABORATORY ANIMALS, (OCT 1992) VOL. 26, NO. 4, PP. 269-280. ISSN: 0023-6772., UNIV UTRECHT, FAC MED, DEPT NEPHROL, UTRECHT, NETHERLANDS;UNIV UTRECHT, FAC MED, DEPT INTERNAL MED, UTRECHT, NETHERLANDS; UNIV UTRECHT, FAC MED, DEPT PHARMACEUT, UTRECHT, NETHERLANDS; ERASMUS UNIV, DE * |
LANCET, (09 MAY 1992) VOL. 339, NO. 8802, PP. 1154-1156. ISSN: 0140-6736., UNIV MINNESOTA, DEPT SURG, BOX 290 UMHC, 420 DELAWARE ST SE, MINNEAPOLIS, MN, 55455 (Reprint) * |
See also references of EP1335704A2 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Also Published As
Publication number | Publication date |
---|---|
EP1335704A2 (en) | 2003-08-20 |
CA2429898C (en) | 2011-02-22 |
WO2002067895A2 (en) | 2002-09-06 |
CA2429898A1 (en) | 2002-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002067895A3 (en) | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent | |
AU2001281277A1 (en) | Methods and devices for delivering a ventricular stent | |
AU2003276098A1 (en) | Expandable medical implant and percutaneous delivery | |
AU5367501A (en) | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | |
WO2005027794A3 (en) | Medical devices | |
WO2003028660A3 (en) | Drug delivery devices and methods | |
AU2001273341A1 (en) | An implantable or insertable therapeutic agent delivery device | |
AU8127701A (en) | Methods and devices for delivering a ventricular stent | |
MXPA03007590A (en) | Compositions and methods for enhancing drug delivery across and into ocular tissues. | |
AU2002240275A1 (en) | Methods and devices for delivering occlusion elements | |
AU2001296217A1 (en) | Magnetically navigated pacing leads, and methods for delivering medical devices | |
AU2003258209A1 (en) | Active agent delivery systems, medical devices, and methods | |
AU2001289098A1 (en) | Implantable prosthesis | |
EP1143935A3 (en) | Controlled-release biocompatible ocular drug delivery implant devices and methods | |
WO2004010975A3 (en) | Controlled drug delivery | |
AU1453602A (en) | Systems, devices and methods for suturing patient tissue | |
AU2001254786A1 (en) | Medical implant | |
AU2001295850A1 (en) | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue | |
AU2001264044A1 (en) | 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof | |
AU2001264042A1 (en) | 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | |
AU2002360717A1 (en) | Controlled release dosage form having improved drug release properties | |
AU2001258443A1 (en) | Drug delivery device, especially for the delivery of gestodene | |
AU2003226770A1 (en) | Intravaginal reservoir drug delivery devices | |
AU2001258442A1 (en) | Drug delivery device, especially for the delivery of levonorgestrel | |
AU2001295979A1 (en) | Medicinal compositions, dose and method for treating malaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2429898 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273052 Country of ref document: EP Ref document number: 2002258361 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001273052 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10432644 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |